## **In The Claims**

Please make the following amendments to Claims 2, 4, 8, 10 and 11 in order to correct typographical/translational errors made in translating into the English language, and to better format the claims for accepted US Patent practice.

A Clean set of the claims after amendment is attached hereto.

- 3. (AMENDED) The cell culture according to Claim 1 wherein the enzyme is NADPH cytochrome P450 reductase, NADPH cytochrome P450, flavin monooxygenase, epoxy hydratase, glucurosyl transferase, sulfotransferase or glutathione S-transferase.
- 4. (AMENDED) The cell culture according to Claim 3 wherein the NADPH cytochrome P450 is CYP1A1, CYP1A2 or CYPA3.
- 8. (Amended) A screening method for a compound or a salt thereof 1) which inhibits or promotes an enzyme activity involved in the metabolism of xenobiotics in the liver or 2) which inhibits or promotes the expression of a gene encoding an enzyme involved in the metabolism of xenobiotics in the liver, <u>said method</u> characterized by the use of the cell culture according to Claim 1 <u>in a screening assay comprising contacting said cell culture with a compound to be tested and detecting enzyme activity or gene expression in said cell culture.</u>
- 10. (AMENDED) An analytical method for <u>assaying</u> (a) enzymes involved in the metabolism of xenobiotics and/or endogenous substrates, (b) metabolic pathways for xenobiotics and/or endogenous substrates, (c) chemical structures of metabolites of xenobiotics and/or endogenous substrates, (d) inhibition of enzymes which metabolize xenobiotics and/or endogenous substrates, (e) promotion of the activity of enzymes which metabolize xenobiotics and/or endogenous substrates, (f) cytotoxicity due to the metabolism xenobiotics and/or endogenous substrates, (h) carcinogenicity due to the metabolism xenobiotics and/or endogenous substrates, (i) mutagenicity due to the metabolism xenobiotics and/or endogenous substrates, (j) hepatotoxicity due to the metabolism xenobiotics and/or endogenous substrates, or (k) hepatic action of xenobiotics and/or endogenous substrates, characterized by the use of the cell culture according

to Claim 1 in an assay comprising contacting said cell culture with a test subject, then assaying for the resultant effect on the cell culture.

11. (Amended) A method of preparing metabolites of xenobiotics and/or endogenous substrates, characterized by the use of the cell culture according to Claim 1 comprising maintaining said cell culture in the presence of xenobiotics and/or endogenous substrates for sufficient time under conditions suitable for the production of metabolites of said xenobiotics and/or endogenous substrates, and producing said metabolites.